骨转换标志物在韩国骨质疏松症中的临床应用
Clinical Application of Bone Turnover Markers in Osteoporosis in Korea.
作者信息
Park So Young, Ahn Seong Hee, Yoo Jun-Il, Chung Youn-Jee, Jeon Yun Kyung, Yoon Byung-Ho, Kim Ha Young, Lee Seung Hun, Lee Jehoon, Hong Seongbin
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.
出版信息
J Bone Metab. 2019 Feb;26(1):19-24. doi: 10.11005/jbm.2019.26.1.19. Epub 2019 Feb 28.
Abstract
Bone turnover markers (BTMs) have important role in the management of osteoporosis. Recently the clinical application of BTMs has achieved significant progress and measurement of BTMs give us better understanding of pathogenesis of osteoporosis. However, the use of BTMs is still insufficient in Korea. We summarized the available methods and standard interval of the BTMs in Korea. Also we reviewed published literatures on pre-analytical variability in the measurement of BTMs and provided recommendations for standardized sample handling and patient preparation for reducing those pre-analytical variabilities. The clinical application of BTMs in patients with chronic kidney disease who have a higher fracture risk than the general population is summarized.
摘要
骨转换标志物（BTMs）在骨质疏松症的管理中具有重要作用。近年来，BTMs的临床应用取得了显著进展，对BTMs的检测使我们对骨质疏松症的发病机制有了更好的理解。然而，在韩国，BTMs的使用仍然不足。我们总结了韩国现有的BTMs检测方法和标准间隔。此外，我们回顾了已发表的关于BTMs检测前分析变异性的文献，并为标准化样本处理和患者准备提供了建议，以减少这些分析前的变异性。本文还总结了BTMs在骨折风险高于普通人群的慢性肾脏病患者中的临床应用。
相似文献
1
Clinical Application of Bone Turnover Markers in Osteoporosis in Korea.骨转换标志物在韩国骨质疏松症中的临床应用
J Bone Metab. 2019 Feb;26(1):19-24. doi: 10.11005/jbm.2019.26.1.19. Epub 2019 Feb 28.
2
Use of Bone Turnover Markers in Clinical Practice for the Management of Osteoporosis in Korea: From the Survey on the Prescription Pattern of Bone Turnover Markers.韩国临床实践中骨转换标志物在骨质疏松症管理中的应用：基于骨转换标志物处方模式的调查
J Bone Metab. 2019 Nov;26(4):271-277. doi: 10.11005/jbm.2019.26.4.271. Epub 2019 Nov 30.
3
[Bone turnover marker].[骨转换标志物]
Nihon Rinsho. 2015 Oct;73(10):1649-58.
4
Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis.骨转换生化标志物在绝经后骨质疏松症管理中的应用。
Clin Chem Lab Med. 2008;46(10):1345-57. doi: 10.1515/CCLM.2008.310.
5
Bone turnover markers: Emerging tool in the management of osteoporosis.骨转换标志物：骨质疏松症管理中的新兴工具。
Indian J Endocrinol Metab. 2016 Nov-Dec;20(6):846-852. doi: 10.4103/2230-8210.192914.
6
The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis.骨转换生化标志物在原发性和继发性骨质疏松症临床管理中的应用。
Endocrine. 2016 May;52(2):222-5. doi: 10.1007/s12020-016-0900-2. Epub 2016 Feb 23.
7
Role of biochemical markers in the management of osteoporosis.生化标志物在骨质疏松症管理中的作用。
Climacteric. 2015;18 Suppl 2:10-8. doi: 10.3109/13697137.2015.1101256. Epub 2015 Oct 27.
8
Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment.关于使用骨转换标志物进行骨质疏松症治疗的立场声明。
J Bone Metab. 2019 Nov;26(4):213-224. doi: 10.11005/jbm.2019.26.4.213. Epub 2019 Nov 30.
9
Biochemical Markers of Bone Turnover and their Role in Osteoporosis Diagnosis: A Narrative Review.骨转换的生化标志物及其在骨质疏松症诊断中的作用：一篇叙述性综述。
Recent Pat Endocr Metab Immune Drug Discov. 2015;9(2):79-89. doi: 10.2174/1872214809666150806105433.
10
Use of bone turnover markers in clinical practice.骨转换标志物在临床实践中的应用。
Curr Opin Endocrinol Diabetes Obes. 2012 Dec;19(6):468-73. doi: 10.1097/MED.0b013e3283591492.
引用本文的文献
1
Association of body mass index and sarcopenia with osteoporosis: a predictive nomogram model for risk assessment.体重指数和肌肉减少症与骨质疏松症的关联：一种用于风险评估的预测列线图模型
Ther Adv Endocrinol Metab. 2025 Apr 28;16:20420188251332055. doi: 10.1177/20420188251332055. eCollection 2025.
2
Association of serum alkaline phosphatase levels with bone mineral density, osteoporosis prevalence, and mortality in US adults with osteoporosis: evidence from NHANES 2005-2018.美国骨质疏松症成年人血清碱性磷酸酶水平与骨密度、骨质疏松症患病率及死亡率的关联：来自2005 - 2018年美国国家健康与营养检查调查（NHANES）的证据
Osteoporos Int. 2025 Feb;36(2):283-297. doi: 10.1007/s00198-024-07324-w. Epub 2024 Nov 29.
3
Effectiveness and Usefulness of Bone Turnover Marker in Osteoporosis Patients: A Multicenter Study in Korea.骨转换标志物在骨质疏松症患者中的有效性和实用性：韩国的一项多中心研究。
J Bone Metab. 2023 Nov;30(4):311-317. doi: 10.11005/jbm.2023.30.4.311. Epub 2023 Nov 30.
4
Intra-Individual Changes in Total Procollagen-Type 1 N-terminal Propeptide in a Korean Adult Population.韩国成年人群中I型前胶原N端前肽的个体内变化
Diagnostics (Basel). 2022 Oct 2;12(10):2399. doi: 10.3390/diagnostics12102399.
5
Long-Term Selenium-Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo-Controlled Trial.长期补充酵母硒对骨转换标志物无影响：一项随机安慰剂对照试验。
J Bone Miner Res. 2022 Nov;37(11):2165-2173. doi: 10.1002/jbmr.4703. Epub 2022 Sep 29.
6
The correlation between serum total alkaline phosphatase and bone mineral density in young adults.年轻人血清总碱性磷酸酶与骨密度的相关性。
BMC Musculoskelet Disord. 2022 May 18;23(1):467. doi: 10.1186/s12891-022-05438-y.
7
Auraptene ameliorates osteoporosis by inhibiting RANKL/NFATc1 pathway-mediated bone resorption based on network pharmacology and experimental evaluation.基于网络药理学和实验评估，金合欢醇通过抑制RANKL/NFATc1通路介导的骨吸收来改善骨质疏松症。
Bone Joint Res. 2022 May;11(5):304-316. doi: 10.1302/2046-3758.115.BJR-2021-0380.R1.
8
A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial.一项多机构随机对照试验，旨在研究唑来膦酸是否能预防地诺单抗停用后的骨质流失：地诺单抗序贯治疗（DST）试验的研究方案。
Front Med (Lausanne). 2021 Sep 8;8:717168. doi: 10.3389/fmed.2021.717168. eCollection 2021.
9
Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures.改善骨质疏松性骨折预测的潜在生物标志物
Endocrinol Metab (Seoul). 2020 Mar;35(1):55-63. doi: 10.3803/EnM.2020.35.1.55.
10
Reference Intervals for Bone Turnover Markers in Korean Healthy Women.韩国健康女性骨转换标志物的参考区间
J Bone Metab. 2020 Feb;27(1):43-52. doi: 10.11005/jbm.2020.27.1.43. Epub 2020 Feb 29.
本文引用的文献
1
Age-related Reference Intervals for Total Collagen-I-N-terminal Propeptide in Healthy Korean Population.韩国健康人群中总I型胶原N端前肽的年龄相关参考区间
J Bone Metab. 2018 Nov;25(4):235-241. doi: 10.11005/jbm.2018.25.4.235. Epub 2018 Nov 30.
2
Management of Osteoporosis in Chronic Kidney Disease.慢性肾脏病中的骨质疏松管理
Intern Med. 2017 Dec 15;56(24):3271-3276. doi: 10.2169/internalmedicine.8618-16. Epub 2017 Oct 11.
3
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论：2017 年 KDIGO 慢性肾脏病-矿物质和骨异常（CKD-MBD）诊治临床实践指南更新。
Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21.
4
Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.CTX-I 和 PINP 作为骨转换标志物的应用：国家骨健康联盟建议规范样本处理和患者准备，以减少分析前的变异性。
Osteoporos Int. 2017 Sep;28(9):2541-2556. doi: 10.1007/s00198-017-4082-4. Epub 2017 Jun 19.
5
The use of bone turnover markers in chronic kidney disease-mineral and bone disorders.骨转换标志物在慢性肾脏病-矿物质和骨异常中的应用
Nephrology (Carlton). 2017 Mar;22 Suppl 2:11-13. doi: 10.1111/nep.13014.
6
Clinical usefulness of bone turnover marker concentrations in osteoporosis.骨转换标志物浓度在骨质疏松症中的临床应用价值
Clin Chim Acta. 2017 Apr;467:34-41. doi: 10.1016/j.cca.2016.06.036. Epub 2016 Jun 30.
7
Diurnal Rhythms of Bone Turnover Markers in Three Ethnic Groups.三个种族群体中骨转换标志物的昼夜节律
J Clin Endocrinol Metab. 2016 Aug;101(8):3222-30. doi: 10.1210/jc.2016-1183. Epub 2016 Jun 13.
8
IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children.IDS iSYS 全自动完整型原胶原 1-N 端前肽检测：成人和儿童的方法评估及参考区间。
Clin Chem Lab Med. 2013 Oct;51(10):2009-18. doi: 10.1515/cclm-2012-0531.
9
Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making.维持性血液透析患者中新骨矿物质代谢标志物的变异性：对临床决策的影响。
Am J Kidney Dis. 2013 May;61(5):847-8. doi: 10.1053/j.ajkd.2012.12.013. Epub 2013 Jan 26.
10
Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition).骨代谢标志物在骨质疏松症诊断和治疗中的临床应用指南（2012 年版）。
J Bone Miner Metab. 2013 Jan;31(1):1-15. doi: 10.1007/s00774-012-0392-y. Epub 2012 Nov 10.
Zotero 插件